Sanofi reported a strong second-quarter performance with a 3.2% increase in operating income and exceeded sales expectations, driven by the success of its blockbuster drug Dupixent.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Sanofi reported a strong second-quarter performance with a 3.2% increase in operating income and exceeded sales expectations, driven by the success of its blockbuster drug Dupixent.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
We are preparing, please wait
This content is only available for premium members. Please become a paid member to access.
Download AppCurrently, memberships can only be purchased through the app.